ArticleCell cycle (Georgetown, Tex.)2013
High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors.
Article in Cell cycle (Georgetown, Tex.), 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03323346 (Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Open Labeled Trial of Disulfiram With Copper in Metastatic Breast Cancer
Who cites it
27 citing papers in PubMed, 51 citations in OpenAlex.
- MYH9: Structure, functions, and therapeutic implications in cancer and genetic disorders.Genes & diseases · 2026Review
- Non-Muscle Myosin II A: Friend or Foe in Cancer?International journal of molecular sciences · 2024Review
- Impact of Molecular Profiling on Therapy Management in Breast Cancer.Journal of clinical medicine · 2024Review
- PDE3B regulates KRT6B and increases the sensitivity of bladder cancer cells to copper ionophores.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Stability-based approaches in chemoproteomics.Expert reviews in molecular medicine · 2024Review
- Challenges and Perspectives in Target Identification and Mechanism Illustration for Chinese Medicine.Chinese journal of integrative medicine · 2023Review
- The Knowns and Unknowns in Protein-Metabolite Interactions.International journal of molecular sciences · 2023Review
- Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line.PloS one · 2023Article
- The emerging role of mass spectrometry-based proteomics in drug discovery.Nature reviews. Drug discovery · 2022Review
- Dehydroquinate Synthase Directly Binds to Streptomycin and Regulates Susceptibility ofFrontiers in microbiology · 2022Article
- Thermosensitive and Conductive Hybrid Polymer for Real-Time Monitoring of Spheroid Growth and Drug Responses.ACS sensors · 2021Article
- IQGAP1 control of centrosome function defines distinct variants of triple negative breast cancer.Oncotarget · 2020Article
- The biological activity of bispecific trastuzumab/pertuzumab plant biosimilars may be drastically boosted by disulfiram increasing formaldehyde accumulation in cancer cells.Scientific reports · 2019Article
- Ras GTPase-Activating-Like Protein IQGAP1 (IQGAP1) Promotes Breast Cancer Proliferation and Invasion and Correlates with Poor Clinical Outcomes.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- Dynamic changes during the treatment of pancreatic cancer.Oncotarget · 2018Article
- CDC25 as a common therapeutic target for triple-negative breast cancer - the challenges ahead.Molecular & cellular oncology · 2018Article
- Discovery of Tamoxifen and N-Desmethyl Tamoxifen Protein Targets in MCF-7 Cells Using Large-Scale Protein Folding and Stability Measurements.Journal of proteome research · 2017Article
- Article
- RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.The Journal of clinical investigation · 2016Article
- Elevation of Kynurenine Metabolites in Rat Liver and Serum: A Potential Additional Mechanism of the Alcohol Aversive and Anti-cancer Effects of Disulfiram?Alcohol and alcoholism (Oxford, Oxfordshire) · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 6 countries.
Funding
Abstract
Triple-negative breast cancer (TNBC) represents an aggressive subtype, for which radiation and chemotherapy are the only options. Here we describe the identification of disulfiram, an FDA-approved drug used to treat alcoholism, as well as the related compound thiram, as the most potent growth inhibitors following high-throughput screens of 3185 compounds against multiple TNBC cell lines. The average IC50 for disulfiram was ~300 nM. Drug affinity responsive target stability (DARTS) analysis identified IQ motif-containing factors IQGAP1 and MYH9 as direct binding targets of disulfiram. Indeed, knockdown of these factors reduced, though did not completely abolish, cell growth. Combination treatment with 4 different drugs commonly used to treat TNBC revealed that disulfiram synergizes most effectively with doxorubicin to inhibit cell growth of TNBC cells. Disulfiram and doxorubicin cooperated to induce cell death as well as cellular senescence, and targeted the ESA(+)/CD24(-/low)/CD44(+) cancer stem cell population. Our results suggest that disulfiram may be repurposed to treat TNBC in combination with doxorubicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.